Clinical trials: Patients With Heart Failure With Reduced Ejection Fraction - HFrEF
- Condition Patients With Heart Failure With Reduced Ejection Fraction - HFrEF
- Funder type Industry (pharma, biotech, devices)
Heart Failure With Reduced Ejection Fraction
Vsling™ I: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure
Prospective, multi-center, open-label clinical study of the feasibility and initial safety and performance of the Vsling™ in patients with heart failure (HF) with evidence of reduced left ventricular ejection fraction, associated…
- Trial name
- NCT06851949
- Testing
- Vsling
- Where
- 5 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Cardiac Success
Heart Failure
REDUCE LAP-HFREF TRIAL
The objective of this pilot study is to evaluate the safety and performance of implanting the IASD® System II in Heart Failure patients with reduced ejection fraction and elevated left sided filling pressures, who remain…
- Trial name
- NCT03093961
- Testing
- IASD implant
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Corvia Medical
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China
This is an observational study in which data from people in China with chronic heart failure with reduced ejection fraction (HFrEF) who will be receiving vericiguat treatment are collected.
- Trial name
- VERI-China (NCT05728502)
- Testing
- Vericiguat (Verquvo, BAY1021189), Standard of Care (SoC)
- Where
- China
- Volunteers
- 2,400 people
- Sponsor
- Bayer
Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Secondary Use of PARALLEL-HF Data
This study utilized the blood and first morning void (FMV) urine samples from the PARALLEL-HF study (core part). The PARALLEL-HF study (core part) was a multicenter, randomized, double-blind, double-dummy, parallel-group…
- Trial name
- NCT07527767
- Where
- Japan
- Volunteers
- 236 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure With Reduced Ejection Fraction, Worsening Chronic Heart Failure
An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions
This is an observational study in which data already collected from people with chronic HFrEF (heart failure with reduced ejection fraction) who have experienced worsening heart failure are studied.
- Trial name
- NCT06632483
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- India
- Volunteers
- 604 people
- Sponsor
- Bayer
Heart Failure
Alleviant ALLAY-HFrEF Study
Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in…
- Trial name
- NCT06812533
- Testing
- Alleviant ALV1 System
- Where
- 70 sites in United States, Australia and 9 more
- Volunteers
- 350 people
- Sponsor
- Alleviant Medical, Inc.
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States
This is an observational study in which data already collected from people with chronic heart failure with reduced ejection fraction (HFrEF) are studied.
- Trial name
- HOVER (NCT06363110)
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- Bayer
Non-Ischemic Heart Failure, Reduced Ejection Fraction Heart Failure
ASCs in Recently Diagnosed Non-ischemic Heart Failure
The goal of this clinical trial is to investigate the efficacy and safety of intravenous infusions of allogeneic adipose tissue-derived mesechymal stromal cells in patients with recently diagnosed non-ischemic heart failure in…
- Trial name
- ARIISE (NCT06840275)
- Testing
- Allogeneic adipose tissue-derived mesenchymal stem cells, Cryostor CS10
- Where
- Denmark
- Sponsor
- Cell to Cure ApS
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
- Trial name
- DAPA-HF (NCT03036124)
- Testing
- Dapagliflozin
- Where
- 419 sites in United States, Argentina and 18 more
- Volunteers
- 4,744 people
- Sponsor
- AstraZeneca
Heart Failure With Reduced Ejection Fraction (HFrEF)
A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure
The primary purpose of the study is to evaluate the safety and efficacy of 2 doses of AC01 compared to placebo over 12 weeks in participants with chronic advanced HFrEF.
- Trial name
- GOAL-HF2 (NCT07584967)
- Testing
- AC01
- Volunteers
- 400 people
- Sponsor
- AnaCardio AB
Heart Failure, Heart Failure, Systolic
COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure
The purpose of this study was to determine the effect of sacubitril/valsartan (LCZ696) vs. Enalapril on improvement in erectile function and ability in male patients with chronic heart failure with reduced ejection fraction and…
- Conditions
- Heart Failure, Heart Failure, Systolic, Erectile Dysfunction
- Trial name
- CONFIDENCE-HF (NCT03917459)
- Testing
- LCZ696, Enalapril
- Where
- 13 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Chronic Heart Failure
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.
- Trial name
- RENEU-HF (NCT06369298)
- Testing
- JK07
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 282 people
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure, Heart Failure NYHA Class II
Heart Failure Management for Patient With CIED Remotely Monitored
This randomized, controlled, open-label, parallel, multicenter clinical study evaluates the efficacy of SmartSignalHF compared with heart failure (HF) remote monitoring (RM) standard of care in implanted patients with heart…
- Conditions
- Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure With Reduced Ejection Fraction (HFrEF)
- Trial name
- PROACT-HF (NCT07247032)
- Testing
- SmartSignalHF, HF RM standard of care
- Where
- France
- Volunteers
- 1,132 people
- Sponsor
- Implicity
Heart Failure With Reduced Ejection Fraction
Phase Ib/IIa Trial With AC01 in Patients With HFrEF
This is a randomized, double-blind, placebo-controlled two-part study with a multiple escalating dose phase followed by a cohort expansion phase to assess safety, tolerability, pharmacokinetics and pharmacodynamics of AC01 in…
- Trial name
- GOAL-HF1 (NCT05642507)
- Testing
- AC01
- Where
- 14 sites in Italy, Netherlands and 2 more
- Volunteers
- 58 people
- Sponsor
- AnaCardio AB
Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
This is an observational study in which data already collected from people with chronic heart failure is studied. Chronic HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body as well…
- Trial name
- ROVER Japan (NCT06697353)
- Testing
- vericiguat (BAY 1021189)
- Where
- Japan
- Volunteers
- 4,936 people
- Sponsor
- Bayer
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting
This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in people with chronic heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT06148935
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- South Korea
- Volunteers
- 1,350 people
- Sponsor
- Bayer
Heart Failure (HF)
A Trial to Study BAY1753011 in Patients With Congestive Heart Failure
To assess the efficacy of 30 mg of BAY1753011, with or without furosemide, versus furosemide alone in patients with heart failure and objective evidence of congestion.
- Trial name
- AVANTI (NCT03901729)
- Testing
- BAY 1753011, Furosemide
- Where
- 66 sites in Austria, Bulgaria and 7 more
- Volunteers
- 482 people
- Sponsor
- Bayer
Chronic Heart Failure With Reduced Ejection Fraction
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction
The purpose of this study is to evaluate the effect of IONIS-AGT-LRX weekly subcutaneous (SC) injection on plasma angiotensinogen (AGT) concentration from Baseline to Study Day 85 (Week 13) and to evaluate the effect of…
- Trial name
- ASTRAAS-HF (NCT04836182)
- Testing
- IONIS-AGT-LRx
- Where
- 19 sites in United States, Hungary and 1 more
- Volunteers
- 72 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Heart Disease, Heart Failure
Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany
Heart failure (HF) is a global public health issue that affects more than 63 million people worldwide. The clinical and economic burden of HF on health care systems is substantial.
- Conditions
- Heart Disease, Heart Failure, Cardiovascular Disease, Heart Failure, Systolic
- Trial name
- PHRASE-HF (NCT06675552)
- Where
- 6 sites in Germany
- Volunteers
- 338 people
- Sponsor
- AstraZeneca
Hearth Failure With Reduced Ejection Fraction (HFrEF)
Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
The primary purpose of the study was to describe the tolerability of treatment with the optimal dose of LCZ696 (97 mg sacubitril / 103 mg valsartan bid), over six (6) months, in patients with heart failure with reduced ejection…
- Trial name
- PARASAIL (NCT02690974)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 32 sites in Canada
- Volunteers
- 302 people
- Sponsor
- Novartis Pharmaceuticals